Personalis (NASDAQ:PSNL) CEO Sells $882,602.82 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 80,091 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $11.02, for a total value of $882,602.82. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $2,600,565.72. This represents a 25.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $11.40 on Monday. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $11.85. The firm has a market capitalization of $1.19 billion, a P/E ratio of -11.18 and a beta of 2.27. The stock has a 50 day moving average price of $6.86 and a 200-day moving average price of $8.10.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. On average, equities analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. BTIG Research lowered their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Morgan Stanley lowered their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Needham & Company LLC lifted their price objective on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research note on Saturday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Personalis has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd raised its stake in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Howland Capital Management LLC increased its holdings in shares of Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after purchasing an additional 3,851 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.